ライフサイエンスコーパス: rationale for

1 ncordance across all AEG types, suggesting a rationale for a biologic classification.

2 elevations, and the present results are the rationale for a genotype-directed clinical trial using m

3 Thus, this study provides a rationale for a novel therapeutic approach to overcome r

4 These results provide a strong rationale for a novel therapeutic strategy selectively t

5 lved in GEM resistance and provides a strong rationale for a PC therapy addressing the combined treat

6 this work may contribute to the preclinical rationale for a precision medicine trial of the WEE1 inh

7 us, this analysis provides a neurobiological rationale for a recently completed clinical study in MS

8 e-stimulated insulin secretion and suggest a rationale for a therapeutic alternative to current treat

9 Our data provide rationale for adding an extra priming dose to those aged

10 Following admission, the documented rationale for additional treatments was guided by physio

11 d adaptive hyperinflammation and support the rationale for an IL-18-driven subclass of hyperinflammat

12 In this review, the rationale for and current status of various vaccine cand

13 and tables with additional details about the rationale for and implementation of each recommendation,

14 The rationale for and knowledge gaps related to each of thes

15 leading an AS program (ASP), we describe the rationale for, and the output and shortcomings of, a ded

16 These findings offer a new rationale for anti-ERK5 therapy to improve cancer patien

17 cognition mechanism and uncovers a molecular rationale for binding of free histone by specialized his

18 ells and glutamatergic neurons, presenting a rationale for brain metastasis.

19 storical perspective, this review provides a rationale for checking factors that will be key for the

20 : Results from this study provide additional rationale for chronic azithromycin use in PA-positive pa

21 of chronic inflammation, offers a compelling rationale for clinical advancement of this proton techni

22 the treatment of TNBC, and provides a strong rationale for clinical development of combination therap

23 These data support the rationale for clinical development of TTK inhibition as

24 These data provide a strong rationale for clinical translation of MI-3454 or its ana

25 toma and PFA ependymoma, thereby providing a rationale for clinical trials of these approaches in hum

26 g OxPL may slow AS progression and provide a rationale for clinical trials to test this hypothesis.

27 We provide strong rationale for clinical use of FFPE-derived RNA based on

28 cancer collective invasion pack and provides rationale for co-targeting PDH and GLUT1 to inhibit coll

29 Results from, timeline and rationale for, cohorts A, B, and C are presented in deta

30 stance, and how the abscopal effect provides rationale for combination strategies with immunotherapy.

31 in vitro model of MEKi resistance provided a rationale for combination therapies.

32 We review the rationale for combination therapy and different strategi

33 immune modulatory effect and supporting the rationale for combination with immune checkpoint blockad

34 tive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeu

35 Our findings provide rationale for combining DEX and RUX to enhance the lymph

36 and IFNgamma, providing a strong mechanistic rationale for combining immunotherapeutics, such as chec

37 d upregulation of PD-L1 expression provide a rationale for combining MYCi with anti-PD-1/PD-L1 therap

38 vated protein kinase pathway that provides a rationale for combining pan-ERBB and mitogen-activated p

39 d-type and BRCA-mutant tumors and provides a rationale for combining PARPi with immunotherapy in pati

40 PD-L1 expression in tumor cells, providing a rationale for combining PD-1/PD-L1 inhibitors with radia

41 e presented data support the mechanism-based rationale for combining the MSLN-TTC with DDR inhibitors

42 ith oncogene targeted therapies, providing a rationale for combining these agents with newly develope

43 ptive anti-tumor immunity and provide strong rationales for combining telomere-targeting therapy with

44 We highlight the scientific rationale for comprehensive and longitudinal TCR analyse

45 in this analysis does not find a scientific rationale for concluding that fluoropolymers are of low

46 Furthermore, the rationale for confirmation is contentious.

47 r endocardium in HLHS etiology and provide a rationale for considering endocardial function in regene

48 dulates glycogen metabolism, this provides a rationale for considering nutrient-physical activity int

49 These findings provide a rationale for continual glucose control in these patient

50 n the pathogenesis of AD and propose a novel rationale for correction of metabolic inflammation, incr

51 der the broad term of "stroke" that form the rationale for current treatment strategies.

52 including the use of nelarabine, and provide rationales for current treatment protocols for both T-AL

53 hromboembolism-prevention trials and provide rationale for de-escalation trials.

54 tion of ictal propagation should inspire new rationales for deep brain stimulation in patients with i

55 ts during development but may also provide a rationale for designing new treatments toward myriad neu

56 is of all such reports helps in developing a rationale for designing purpose-built molecular probes o

57 These results provide strong pre-clinical rationale for developing and testing LOX inhibitors to o

58 These results establish a strong rationale for developing kinase-directed inhibitors of I

59 Our studies thus provide a rationale for developing NK cell-based therapies to effe

60 is primary blood product, providing a strong rationale for developing recombinant alternatives.

61 These preclinical data provide a strong rationale for developing saroglitazar for the treatment

62 tinal microbiota and enteropathy and offer a rationale for developing therapies that target these mic

63 d affect-related behaviors, provide a strong rationale for developing this drug class as a treatment

64 inflammatory heat hypersensitivity provide a rationale for developing TRPM3 antagonists to treat path

65 eceptor 3-mediated mechanism and support the rationale for development of more-specific receptor modu

66 These results provide a mechanistic rationale for directing SPA therapy to PCs with AR ampli

67 thereby inducing cmo These results provide a rationale for directly targeting SYK and its downstream

68 In conclusion, our findings provide a rationale for drug repositioning trials investigating co

69 Although there is a strong biological rationale for early decompression of the injured spinal

70 Our studies provide a mechanistic rationale for efficacy of PARPi in cancer cells lacking

71 Overall, our study provides a rationale for employing coarse Raman mapping to substant

72 ur findings also suggest a strong scientific rationale for enhancing PD-1/PD-L1-targeted cancer immun

73 ndent clinical data, these results provide a rationale for ensuing clinical trials aimed at incorpora

74 These findings give a rationale for epidemiologic studies of air pollution to

75 gs, along with the structural and functional rationale for epitope conservation, provide insights for

76 Because there is increasing rationale for establishing both targeted and universal s

77 Our findings provide strong rationale for examining treatment effect modifications b

78 KRAS-mediated chemoresistance and provide a rationale for exploiting metabolic reprogramming in panc

79 K signaling in iMCD-TAFRO pathogenesis and a rationale for exploring inhibition of the MAPK pathway a

80 This study provides preclinical rationale for exploring the combination of MAPK pathway

81 survival in ccRCC and provide a preclinical rationale for exploring the therapeutic potential of hig

82 These data provide a strong rationale for extension of clinical trials of 9-ING-41 t

83 afer anticoagulants are needed, provides the rationale for factor XII and XI as targets for such agen

84 opoietic cell transplantation, providing the rationale for further evaluation of PHIs, in the prevent

85 Our findings provide a compelling rationale for further in vivo evaluation of the combinat

86 Our results establish a rationale for further investigation of combined BET and

87 Overall, our data provide a strong rationale for further investigation of novel combination

88 regulation after TBI provides a platform and rationale for further prospective investigation of the l

89 These data support the rationale for further study of the effects of mTOR inhib

90 These findings offer a preclinical rationale for further testing of the use of radiation in

91 of future crystal structures and provides a rationale for future in vitro testing that is more sophi

92 These findings provide the rationale for future interventional studies to explore n

93 ollectively, these data provide a compelling rationale for future investigation of Nutlin-3A as an ap

94 Our study also provides a compelling rationale for future testing of PD-L1 checkpoint inhibit

95 nalyse their clinical features and provide a rationale for genetic screening.

96 The rationale for genome-wide association study (GWAS) resul

97 of suboptimal hairpin processing provides a rationale for genomic retention of certain miRNA operons

98 increased incidence of invasive disease, and rationale for global surveillance.

99 his inhibition, thus providing a mechanistic rationale for heterotrimerization with the KAP subunit f

100 g5-mediated transglycosylation, we provide a rationale for how GPI-CWPs are specifically sorted towar

101 s, for the first time, provide a mechanistic rationale for how NAC can prevent the onset of metabolic

102 4 different amino acid ligands, providing a rationale for how the LBD binding site evolved to accomm

103 hosphorylation, aimed to provide a molecular rationale for human mutations that result in learning di

104 y of corals to ocean warming, but provides a rationale for human-assisted migration to restore cooler

105 This landmark study establishes the rationale for identification, subtyping, and deep charac

106 setting for HCC, focusing on the underlying rationale for immunotherapies, which patients may benefi

107 s noninvasive nature, our findings provide a rationale for in vivo studies using Raman spectroscopy,

108 168 at DNA double-strand breaks, providing a rationale for increased homology-directed recombination

109 of calcineurin 'signalosomes' may provide a rationale for inhibiting the phosphatase in disease.

110 inase complex, but will also provide a novel rationale for inhibitor development in the future.

111 We discuss the rationale for integrating care for people with mental di

112 However, a rationale for intraarterial delivery and BBB opening whe

113 failure in COVID-19 patients and provides a rationale for investigating complement inhibitors in fut

114 s key anti-inflammatory effects, providing a rationale for investigation into the repurposing of stat

115 This article reviews NIBS methodology, rationale for its application to ALS and progress to dat

116 ivity to SARS-CoV-2 mutants provide a strong rationale for its evaluation as a COVID-19 therapeutic.

117 t of p53 function that would provide a clear rationale for its frequent inactivation in human cancer.

118 For each principle, we provide a rationale for its inclusion and provide examples where t

119 arrier to resistance, thus strengthening the rationale for its inclusion in rational HCV vaccine desi

120 Despite scientific rationale for its role in AS, the clinical utility of ci

121 of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtype

122 egulator of Wnt receptor turnover provides a rationale for its tumor suppressive function and reveals

123 reduced ejection fraction, with theoretical rationale for its use in HF with preserved ejection frac

124 Our results provide an evolutionary rationale for lack of ExoN-AA reversion, illuminate pote

125 ts of non-European ancestry, and bolster the rationale for large-scale GWAS in diverse human populati

126 Herein, we summarize the pathobiological rationale for local cytoreduction and the potentially sy

127 to as Screening Planning and Implementation RAtionale for Lung cancer (SPIRAL).

128 to insults, these findings provide a further rationale for maintaining DG neurogenesis in adult life.

129 Together, our findings provide a rationale for mechanism-based therapeutic approach that

130 In this report, we provide rationale for modifications (IWG 2018) of these recommen

131 and patients with diabetes mellitus provides rationale for monitoring these asthma subgroups for poor

132 This mechanism provides a rationale for multiple therapeutic approaches.

133 ggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK

134 or period components of trends can provide a rationale for new research or point to clues on the effe

135 This review details the rationale for NMP protocols considering duration of NMP

136 This work provides a fundamental biochemical rationale for nonredundant roles of these RNA demethylas

137 Our results provide rationale for novel therapeutic approaches targeting HIV

138 stem cell state and function and provides a rationale for Nrf2 as a therapeutic target in stem cell-

139 This provides a sound rationale for optimizing venous return during significan

140 published reports and present concepts and a rationale for our emerging hypothesis of a dysfunctional

141 ctures of paralogous complexes, we provide a rationale for our observations.

142 or pancreas only rejections, all support the rationale for pancreas biopsies.

143 ormal tissue dose were observed, providing a rationale for patient-specific dosing.

144 n and BZH in patients with EoE and provide a rationale for pharmacologic intervention of ANO1 functio

145 Together, our findings provide a rationale for pharmacological blockade of the AXL signal

146 ctor for economic development and provided a rationale for policies aiming at a more balanced age str

147 istance than is Mcl-1 and provide biological rationale for potential synergy between ibrutinib and ve

148 recruitment of TEADs and NFIs, indicating a rationale for preclinical studies to block the interacti

149 The most common rationale for prescribing antibiotics with bone grafting

150 ial lipid transfer molecule, structure-based rationale for previously reported disease-causing mutati

151 This provides a rationale for prospective studies on standardized survei

152 However, there is a strong business rationale for protecting local resident employees throug

153 These studies provide a rationale for pursuing enantiomerically pure RJW100 deri

154 s for no longer than required, provide clear rationale for quarantine and information about protocols

155 on on pediatric hepatocellular carcinoma and rationale for recommendations can be found in Appendix E

156 sions: The panel formulated and provided the rationale for recommendations on selected diagnostic and

157 al immunization studies that provide a clear rationale for renewed efforts to develop a CD8(+) T cell

158 These findings provide a rationale for renewed examination of regional astrocytes

159 These findings challenge the treatment rationale for restoring somatotopic representations in c

160 These findings provide a strong rationale for rethinking the pathophysiological role of

161 This article discusses the rationale for returning individual research results to s

162 The rationale for safety concerns at this field strength are

163 ed and future applications, and to provide a rationale for selecting optical technologies for molecul

164 ncanonical binding mode in CLK1, providing a rationale for selectivity over the closely related CLK3

165 mpact CVD risk, and 4) is there a sufficient rationale for setting a target for maximally reducing di

166 To illuminate the rationales for sharing data, the technical challenges an

167 The majority of studies failed to provide rationale for single-sex studies or the lack of sex-base

168 ign considerations for industry and provides rationale for some of the recommendations included in th

169 e from all other flavodoxins that provides a rationale for stabilization of the anionic semiquinone a

170 There is a rationale for studying EPCR in hemophilia.

171 ssant response in humans and provide further rationale for studying gamma power changes as potential

172 evasion within these cells suggest a strong rationale for studying the link between oral infection a

173 empirical and the underlying mechanisms and rationale for success are unknown.

174 lying the development of PD and provided the rationale for surgical procedures, the search to underst

175 Despite the existing rationale for targeting activated KRAS and its downstrea

176 with MYBL2 amplification, and establish the rationale for targeting B-Myb to restore cell cycle cont

177 vivo, and/or in humans) and provide a strong rationale for targeting BRD2/BRD4 for disease treatment

178 Our findings thus provide a rationale for targeting CDK6 in MPN.

179 NER through DDB2 stabilization, suggesting a rationale for targeting EZH2 beyond its catalytic activi

180 Herein the rationale for targeting GPVI is summarized and the publi

181 o maintaining its expression and providing a rationale for targeting IL-1alpha to minimize the role o

182 in lung carcinogenesis that will inform the rationale for targeting its related regulatory signaling

183 This review provides compelling rationale for targeting lysosomes in future therapeutics

184 activation in PC pathogenesis and provide a rationale for targeting MAOA in stromal cells to treat P

185 These findings provide the rationale for targeting metabolic processes as a noncont

186 This study provides further rationale for targeting Mst1r as a therapeutic strategy.

187 discuss what is known about the preclinical rationale for targeting other members of the DDR pathway

188 is amplified in colon tumors and suggests a rationale for targeting Rb phosphorylation in colon canc

189 ncreasing proteasome capacity, and provide a rationale for targeting such patients with PI/RAF or PI/

190 Our findings provide a rationale for targeting the Plasmodium DSB repair pathwa

191 owth in preclinical models, providing strong rationale for targeting the UPR in these cancers.

192 It provides a rationale for targeting VRAC for the treatment of stroke

193 The study provides compelling rationale for testing combinations of high-dose AA and a

194 These data provide rationale for testing GSK3 inhibitors in lymphoma patien

195 risk stratification of this disease, and the rationale for testing targeted therapies in this high-ri

196 Overall, the data provide a strong rationale for the advanced evaluation of HSD17B12 inhibi

197 These findings provide rationale for the assessment of KEs as a treatment for p

198 sults provide a structural and computational rationale for the catalytic versatility of NzeB, as well

199 on bacterial metabolites, the data provide a rationale for the chemical variability of M. hentscheli

200 Thus, our study provided a rationale for the clinical application of CDK4/6 inhibit

201 C-I molecules for degradation, and provide a rationale for the combination of autophagy inhibition an

202 These findings lend rationale for the common practice of attempting to allev

203 xpected until 2021, we feel that sharing the rationale for the design of TRANSEURO, along with the le

204 Our results provide a rationale for the determinants that govern the binding a

205 phasized in the context of the framework and rationale for the development and testing of therapeutic

206 studies with mGlu2/3 agonists, providing the rationale for the development of HDAC2 inhibitors as a n

207 compounds in all the inaja flours provides a rationale for the development of new food and non-food p

208 es of mouse and bacterial TSPO and propose a rationale for the development of new ligands for the pro

209 These findings may provide rationale for the development of new therapies to treat

210 These findings provide a strong rationale for the development of PDI inhibitors and thei

211 understanding of UTUC biology and provide a rationale for the development of UTUC-specific treatment

212 These findings provide a rationale for the dramatic response to targeted therapy.

213 leukemia (AML) with mutated NPM1 provides a rationale for the evaluation of gemtuzumab ozogamicin (G

214 Along with providing the scientific rationale for the evaluation of TGFbeta and PD1 co-block

215 We provide a rationale for the experimentally observed kinetics of mo

216 Here we report a rationale for the formation of the (R)-configured produc

217 A mechanistic rationale for the formation of these products is advance

218 blockade in this disease and also provides a rationale for the future use of adoptive T cell therapy

219 These results present a rationale for the generation of SHOC2 phosphatase target

220 This study provides a rationale for the genome-wide characterization of MSI in

221 We discuss the rationale for the guidelines and their general content,

222 Docking studies provide a rationale for the high regio- and enantioselectivity of

223 lso performed, providing a molecular orbital rationale for the highly regioselective arene iodination

224 Our data provide preclinical rationale for the implementation of these lncRNAs and WD

225 erature on the biology of MGUS and provide a rationale for the improved identification of high-risk M

226 We outline a rationale for the inclusion of children in COVID-19 ther

227 s work provides a kinetic, control-theoretic rationale for the inclusion of partially redundant enzym

228 Our results provide a rationale for the inclusion of patients with advanced bl

229 s at Dscam2 mutant active zones, providing a rationale for the increase in synaptic strength.

230 Furthermore, we provide a structural rationale for the inhibitory mechanism of ligelizumab.

231 In addition, we provide a molecular rationale for the interaction of the different photoisom

232 R bound to netupitant establish a structural rationale for the lack of basal activity in NK(1)R.

233 tion in multiple hosts provides a compelling rationale for the maintenance of the microbiome homeosta

234 ellent agreement with experiments and offers rationale for the Mg-battery failure in EC electrolyte a

235 T study of the reaction mechanism provides a rationale for the observed reactivity and detailed infor

236 nalization protocol, including computational rationale for the observed regioselectivity, is also des

237 erritin solubility and function, providing a rationale for the presence of ferritin aggregates in cel

238 These findings also provide a rationale for the previously described "olfactory lens,"

239 ors in a pan-cancer setting, and provide the rationale for the repurposing of mitochondrial inhibitor

240 Maximum entropy also provides a physical rationale for the selection of species.

241 thesis of the paraherquamides and provided a rationale for the selective spirocyclization of these po

242 We attempt to provide a rationale for the selectivity for monooxygenation, which

243 counts attributable to introns, provide the rationale for the simultaneous consideration of both exo

244 Our theory provides a unified microscopic rationale for the subtle structure-dynamics-function lin

245 Our results provide a strong rationale for the use of anti-PD-L1 blockade in the trea

246 iac electrical activity, this study provides rationale for the use of btb-ER representations as predi

247 17q23-amplified breast cancer and provide a rationale for the use of centrosome-targeting therapeuti

248 These findings provide a rationale for the use of chicken BCO as a human-relevant

249 These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, incl

250 physiology in non-hyperaemic conditions, the rationale for the use of non-hyperaemic coronary pressur

251 rived measurements, and provide a compelling rationale for the use of PAC monitoring in patients with

252 al for GvHD diagnosis, and there is a strong rationale for the use of PET tracers that can monitor T-

253 mimic the human airway strongly supports the rationale for the use of PilA as a vaccine immunogen to

254 Our findings provide a rationale for the use of selumetinib and AZD8186 in pati

255 These data thus provide a strong mechanistic rationale for the use of tES in humans and will help gui

256 In this review, we provide a rationale for the use of WGS with pedigrees in modern ps

257 e hERG1 intracavitary site provides a simple rationale for the well established state-dependence of d

258 m the American Heart Association, we provide rationale for the widespread adoption of rapid diet scre

259 scovery of these functional disulfides and a rationale for their facile nature has been aided by the

260 ns, and provided a component in the original rationale for their use in patients with COVID-19, may,

261 These data provide a rationale for therapeutic inhibition of FGL2 in brain tu

262 1 in MM cell growth and provides preclinical rationale for therapeutic strategies targeting HUWE1 in

263 es into non-tumorigenic progeny, providing a rationale for therapeutic strategies that specifically e

264 derlies T cell leukemogenesis, and provide a rationale for therapeutic targeting of oncogenic MYC via

265 NA transcription in cancer cells and offer a rationale for therapeutic targeting of UBF1- and ECT2-st

266 The rationale for these cell therapy trials is derived from

267 usly unknown beta-turn provides a structural rationale for these ligands' respective biological activ

268 A mechanistic rationale for these observations is provided.

269 in the range 122 <= lambda <=155 nm offer a rationale for this apparent depletion; the quantum yield

270 Here we provide the scientific rationale for this approach in the hope that researchers

271 The rationale for this approach is that a distorted wavefron

272 en AURKB and Haspin, which provides a strong rationale for this combination therapy for cancer patien

273 The main rationale for this database is to be able to derive mech

274 The rationale for this decision was the lack of specific pat

275 ach KR1-F(ab) complex provided a mechanistic rationale for this difference.

276 ynamic binding data presented here provide a rationale for this isoform difference.

277 ors of arsenic import, providing a potential rationale for this pathway.

278 The biological rationale for this phenomenon is to promote physiologica

279 suffers from diminishing returns, providing rationale for time-limited trials of critical care and s

280 The rationale for tocilizumab treatment is supported by dete

281 wing benefit from levothyroxine therapy, the rationale for treatment is based on the potential for de

282 cribe conflict with families, and to provide rationale for treatment limitations.

283 These data provide a rationale for treatments effective in depression and sch

284 pression studies do not yet provide a strong rationale for trials of checkpoint inhibitor therapy for

285 tegies are ongoing; however, the mechanistic rationale for tumor-specific targeting of immune checkpo

286 y the HLA polymorphic framework, providing a rationale for understanding differences in clinical asso

287 This model, therefore, provides a compelling rationale for understanding how different mutations coop

288 upon ligand binding illuminate a mechanistic rationale for understanding TRPC6 modulation.

289 hophysiology of primary HLH, the therapeutic rationale for use of IFN-gamma-targeting therapy, and po

290 Collectively, our results provide a rationale for using 8a as a tool compound for functional

291 of the failing myocardium and to discuss the rationale for using a combined treatment strategy to fur

292 Only 45 SMTs (37.8%) provided the rationale for using a split-mouth design.

293 The mechanism of action and the rationale for using biologics in periodontal plastic sur

294 ate and adaptive immune cells, and provide a rationale for using CD40L-overexpressing CAR T cells to

295 Overall, these results provide a mechanistic rationale for using PARPi as immunomodulatory agents to

296 These results provide a rationale for using SCF(FBXW7) inhibitors in the treatme

297 Furthermore, the rationale for using weight-band dosing instead of flat-d

298 lationship of smNBEs in these reactions, and rationales for using smNBEs in many cases have also been

299 lerability of DAA therapy has also created a rationale for utilizing HCV-viremic (HCV-RNA-positive) d

300 rts viperin; they also provide a biochemical rationale for viperin's recently discovered role in regu